Tag Archives: Anil Diwan

Business, Finance, Occupation & Industry

NanoViricides President Dr. Diwan Invited to Present a Seminar at the Center for Biological Physics

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

NanoViricides President Dr. Diwan Invited to Present a Seminar at the Center for Biological Physics and the California NanoSystems Institute at UCLA

WEST HAVEN, Conn.–(BUSINESS WIRE)– NanoViricides, Inc. (OTC BB: NNVC) (the “Company”) announced today that its President, Dr. Anil Diwan, has been invited to present a seminar at the University of California, Los Angeles. This seminar will be hosted by the Center for Biological Physics, jointly with the California NanoSystems Institute. The seminar is scheduled for Friday, 22nd of March.

“I am honored to have this opportunity to discuss our work with eminent biophysicists that are researching the interactions and structural stability of viruses,” said Anil Diwan, PhD, President of the Company, adding, “Biophysics is the key to understanding our approach to develop nanoviricides®, our novel biomimetic agents designed to destroy viruses.”

Dr. Diwan’s talk is entitled “Designing a Nanoviricide ® – Biophysics is the Key”.

A “nanoviricide ®”, is a biomimetic decoy designed to fool a virus particle into binding to it and thereby capturing the virus particle and rendering it harmless. It is constructed by chemically attaching virus-binding ligands to a polymeric micelle. Biophysics is of prime importance in designing these structures. The biomimetic ligands tend to have poor energies of interaction with the virus particle per ligand, yet a large number of ligands enable a successful interaction with the virus particle. Additionally, the nanoviricide competes with cells for binding to the virus particle, and must provide a substantially more efficient interaction than the cell-virus interaction, in order to achieve a therapeutic effect. The nanoviricide also must be able to exercise its effect in the biological matrix, be it in the bloodstream, plasma, mucosa, or other extracellular spaces. Further, it should have minimal undesirable interaction with the matrix and host cells so that sufficient material is available for clearing out a fulminant viral infection from a patient’s body. In addition, the nanoviricide needs to be able to distribute itself within the body, across various barriers, so that it can reach the spaces where the virus particles are present. NanoViricides, Inc. has demonstrated that highly effective antiviral treatments can be created against a large number of viruses, despite these design challenges. The challenges and opportunities for understanding the behavior of virus-nanoviricide interactions, and the results from studies of nanoviricides development against various viruses such as influenza, HIV, Herpesvirus, adenoviruses, Dengue viruses, will be discussed.

The first ever orally active nanomedicine has been developed by NanoViricides, Inc. This oral anti-influenza drug candidate has shown very high bioavailability. NanoViricides also has an injectable anti-influenza drug in development towards clinical studies for serious cases of influenza. A pre-IND meeting with the FDA has helped the Company …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

NanoViricides to Lead Sessions at the Symposium on Nanomedicines- Roadmap to Commercialization, in R

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

NanoViricides to Lead Sessions at the Symposium on Nanomedicines- Roadmap to Commercialization, in Rockville, MD tomorrow

WEST HAVEN, Conn.–(BUSINESS WIRE)– NanoViricides, Inc. (OTC BB: NNVC) (the “Company”) announced today that its President, Dr. Anil Diwan, will lead the Section 1, “Designing Nanomedicines“, with Dr. Mostafa Analoui of the Livingston Group. In addition, Dr. Randall Barton, the Company’s Chief Scientific Officer, will lead Section 2, “Preclinical Pharmacology”, with Dr. Benjamin Yerxa of Liquidia Technologies. These sections are part of the Symposium on Nanomedicines: Charting a Roadmap to Commercialization, which is divided into five sections. The Symposium is being held at the Hilton Hotel in Rockville, MD, on the 6th and 7th of March. Section 1 is scheduled for tomorrow, March 6th, at 10:0 am, and Section 2 follows the same day at 11:30am.

The section 1 on “Designing Nanomedicines” is organized to provide a sampling of the multi-faceted nanomedicine technologies and their current and future applications. Panel presenters include: Professor Philip S. Low, Purdue University, Professor Edith Mathiowitz, Brown University, Professor Justin Hanes, Johns Hopkins University, Dr. Uma Prabhakar, Office of Cancer Nanotechnology Research at NCI-NIH, and Dr. Frank Bedu-Addo, PDS Biotechnologies, in addition to Dr. Diwan and Dr. Analoui. The panelists will briefly present design aspects of their respective work in nanomedicines and then discuss several key questions that should be addressed in developing novel nanomedicines against diseases that currently have no good drugs.

Dr. Diwan will focus on the questions of how to design antiviral biomimetic nanomedicines, as exemplified by nanoviricides®, how important is the direct, zip-code-like “active” targeting for such drugs, the Company’s success in developing the first ever orally active nanomedicine (oral FluCide™ anti-influenza drug candidate), success in achieving “broad-spectrum” effectiveness, successful design of ocular delivery, and success in achieving long, sustained, in-vivo effectiveness, as exemplified by the Company’s anti-HIV as well as anti-Influenza drug candidates. The sustained effect may enable single dose therapy for influenza and other acute viral illnesses. In addition, this sustained effect property should result in strong patient benefits for HIV/AIDS patients by reducing the number of times the drug needs to be taken, to perhaps as little as once-a-week.

A single course treatment for out-patients is a highly sought after goal in influenza therapeutics. In addition, broad-spectrum effectiveness against most, if not all, influenza viruses is very important because the influenza A virus changes rapidly every season. During the 2009 H1N1 “swine flu” pandemic, approximately 61 million cases of out-patient influenza were estimated in the USA alone.

The Company’s anti-influenza clinical drug candidate is expected to be …read more
Source: FULL ARTICLE at DailyFinance